Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has announced that the US District Court of New Jersey has granted the company's motion for summary judgment of no inequitable conduct.
Subscribe to our email newsletter
AstraZeneca had sued Teva Pharmaceutical Industries and Sandoz, alleging infringement of AstraZeneca’s patent as a result of Teva’s and Sandoz’s filings of abbreviated new drug spplications (ANDAs). The ANDAs sought approval to market generic versions of Seroquel tablets in the US before Seroquel’s patent expires in 2011.
AstraZeneca’s motion for summary judgment of no inequitable conduct sought judgment on all of the remaining liability issues in the case. Teva and Sandoz had already conceded infringement and the validity of AstraZeneca’s patent.
David Brennan, CEO of AstraZeneca, said: “We are pleased with the court’s decision to uphold our valid intellectual property. Seroquel remains an important part of our company’s portfolio benefiting patients and physicians throughout the world.”